Equity Issuances

Avalon GloboCare Corp. issued Series A-2 warrants to purchase up to 6,372,550 shares of Common Stock of warrant to institutional investors for Each Warrant has an exercise price of $0.51 per share.

“On February 26, 2026, Avalon GloboCare Corp. (the " Company ") entered into securities purchase agreements (the " Purchase Agreements ") with certain institutional investors ("the " Purchasers ") for the issuance and sale in a private placement (the " Private Placement ") of (i) 490,197 shares (the "Shares") of the Company's common stock, par value $0.0001 per shares (" Common Stock ") at a purchase price of $0.51 per Share; (ii) pre-funded warrants (the "Pre-Funded Warrants") at a purchase price of 0.5099 per Pre-Funded Warrant to purchase up to an aggregate of 5,882,353 shares of Common Stock (the " Pre-Funded Warrant Shares "); (iii) Series A-1 warrants to purchase up to 6,372,550 shares of Common Stock (the " Series A-1 Warrants ," and the shares issuable upon exercise thereof, the " Series A-1 Warrant Shares ") and (iv) Series A-2 warrants to purchase up to 6,372,550 shares of Common Stock (the " Series A-2 Warrants ," together with the Series A-1 Warrants, the " Warrants ") and t”

Avalon GloboCare Corp. issued Series A-1 warrants to purchase up to 6,372,550 shares of Common Stock of warrant to institutional investors for Each Warrant has an exercise price of $0.51 per share.

“On February 26, 2026, Avalon GloboCare Corp. (the " Company ") entered into securities purchase agreements (the " Purchase Agreements ") with certain institutional investors ("the " Purchasers ") for the issuance and sale in a private placement (the " Private Placement ") of (i) 490,197 shares (the "Shares") of the Company's common stock, par value $0.0001 per shares (" Common Stock ") at a purchase price of $0.51 per Share; (ii) pre-funded warrants (the "Pre-Funded Warrants") at a purchase price of 0.5099 per Pre-Funded Warrant to purchase up to an aggregate of 5,882,353 shares of Common Stock (the " Pre-Funded Warrant Shares "); (iii) Series A-1 warrants to purchase up to 6,372,550 shares of Common Stock (the " Series A-1 Warrants ," and the shares issuable upon exercise thereof, the " Series A-1 Warrant Shares ") and (iv) Series A-2 warrants to purchase up to 6,372,550 shares of Common Stock (the " Series A-2 Warrants ," together with the Series A-1 Warrants, the " Warrants ") and t”

Avalon GloboCare Corp. issued pre-funded warrants to purchase up to 5,882,353 shares of Common Stock of warrant to institutional investors for $0.5099 per Pre-Funded Warrant.

“On February 26, 2026, Avalon GloboCare Corp. (the " Company ") entered into securities purchase agreements (the " Purchase Agreements ") with certain institutional investors ("the " Purchasers ") for the issuance and sale in a private placement (the " Private Placement ") of (i) 490,197 shares (the "Shares") of the Company's common stock, par value $0.0001 per shares (" Common Stock ") at a purchase price of $0.51 per Share; (ii) pre-funded warrants (the "Pre-Funded Warrants") at a purchase price of 0.5099 per Pre-Funded Warrant to purchase up to an aggregate of 5,882,353 shares of Common Stock (the " Pre-Funded Warrant Shares "); (iii) Series A-1 warrants to purchase up to 6,372,550 shares of Common Stock (the " Series A-1 Warrants ," and the shares issuable upon exercise thereof, the " Series A-1 Warrant Shares ") and (iv) Series A-2 warrants to purchase up to 6,372,550 shares of Common Stock (the " Series A-2 Warrants ," together with the Series A-1 Warrants, the " Warrants ") and t”

Avalon GloboCare Corp. issued 490,197 shares of common stock to institutional investors for $0.51 per Share.

“On February 26, 2026, Avalon GloboCare Corp. (the " Company ") entered into securities purchase agreements (the " Purchase Agreements ") with certain institutional investors ("the " Purchasers ") for the issuance and sale in a private placement (the " Private Placement ") of (i) 490,197 shares (the "Shares") of the Company's common stock, par value $0.0001 per shares (" Common Stock ") at a purchase price of $0.51 per Share; (ii) pre-funded warrants (the "Pre-Funded Warrants") at a purchase price of 0.5099 per Pre-Funded Warrant to purchase up to an aggregate of 5,882,353 shares of Common Stock (the " Pre-Funded Warrant Shares "); (iii) Series A-1 warrants to purchase up to 6,372,550 shares of Common Stock (the " Series A-1 Warrants ," and the shares issuable upon exercise thereof, the " Series A-1 Warrant Shares ") and (iv) Series A-2 warrants to purchase up to 6,372,550 shares of Common Stock (the " Series A-2 Warrants ," together with the Series A-1 Warrants, the " Warrants ") and t”

Edgemode, Inc. issued 400,000,000 shares of the Company's restricted common stock of common stock to BAIF or its assignees.

“exchange the stock options to purchase an aggregate of 400,000,000 shares of common stock of the Company issued to BAIF or its assignees issued under the Joint Venture Agreement for 400,000,000 shares of the Company’s restricted common stock”

VISTA CREDIT STRATEGIC LENDING CORP. issued 1,026,690.050 shares of Class I common stock and 19,358.196 shares of Class S common stock of common stock to accredited investors and non-U.S. persons for $20,263,670.

“Total Consideration As of March 2, 2026 (number of shares finalized on March 24, 2026) 1,026,690.050 shares of Class I common stock 19,358.196 shares of Class S common stock $20,263,670 The sales of Common Stock were made pursuant to subscription agreements entered into by the Company and its investors. The issuances of the Common Stock are exempt from the”

KKR FS Income Trust issued 941,554.363 Class I shares of common stock to accredited investors for aggregate consideration of approximately $27.832 million.

“On March 2, 2026, KKR FS Income Trust (the “Company”) issued and sold 941,554.363 Class I shares (the “Class I Shares”) of the Company’s common shares of beneficial interest (the “Shares”) (with the final number of Class I Shares issued being determined on March 20, 2026) pursuant to subscription agreements entered into with the participating investors for aggregate consideration of approximately $27.832 million”

KKR FS Income Trust Select issued 769,073.832 Class I shares of common stock to accredited investors for $19.534 million.

“On March 2, 2026, KKR FS Income Trust Select (the “Company”) issued and sold 769,073.832 Class I shares (the “Class I Shares”) of the Company’s common shares of beneficial interest (the “Shares”) (with the final number of Class I Shares issued being determined on March 20, 2026) pursuant to subscription agreements entered into with the participating investors for aggregate consideration of approximately $19.534 million .”

Caring Brands, Inc. issued additional shares of Series A Preferred Stock of preferred stock for up to $4.0 million.

“The Purchaser shall have the right, exercisable at any time and from time to time, to purchase up to $4.0 million of additional shares of Series A Preferred Stock and Warrants from the Company (the AIR”),”

Caring Brands, Inc. issued 9,473,685 warrants to acquire up to 9,473,685 shares of Common Stock of warrant to one accredited investor for aggregate purchase price was $3,600,000.

“the Common Warrants and the conversion of the Series A Preferred Stock are both subject to beneficial ownership limitations set by the holder. The aggregate purchase price was $3,600,000. In addition, the Company will not issue any shares upon the exercise of the Warrants or the conversion of the Series A Preferred Stock to the extent that the aggregate issuances”

Caring Brands, Inc. issued 3,789,474 shares of its Series A Convertible Preferred Stock of preferred stock to one accredited investor for aggregate purchase price was $3,600,000.

“the Common Warrants and the conversion of the Series A Preferred Stock are both subject to beneficial ownership limitations set by the holder. The aggregate purchase price was $3,600,000. In addition, the Company will not issue any shares upon the exercise of the Warrants or the conversion of the Series A Preferred Stock to the extent that the aggregate issuances”

Turn Therapeutics Inc. issued shares of Common Stock with an aggregate value of $1.2 million of common stock to Avenue Venture Opportunities Fund II, L.P..

“the Company issued to the Lender shares of Common Stock with an aggregate value of $1.2 million, with the exact number of shares calculated by dividing (i) $1.2 million by (ii) the volume-weighted average price of the Common Stock, determined for the five (5) consecutive trading days ending on the last trading day immediately preceding the Closing Date (the “Equity Grant”).”

JFB Construction Holdings issued common stock.

“the Company announced that the Board of Directors of the Company has approved a forward stock split of the Company’s issued and outstanding shares of common stock”

Audax Private Credit Fund, LLC issued 456,132.001 of common stock for $11.5 million.

“On February 1, 2026, Audax Private Credit Fund, LLC (the “ Fund ”) sold limited liability company interest (the “ Shares ”). The purchase price per share and number of Shares issued was finalized on March 20, 2026. The purchase price per share was equal to $25.212. The following table details the Shares sold: Date of Issuance Common Shares Issued Total Consideration (in millions) February 1, 2026 456,132.001 $ 11.5”

Apollo Origination II (Levered) Capital Trust issued 2,506,748.9395 of common stock to certain investors for $65,000,000.

“The following table details the amount of Shares sold and consideration therefor: Date of Unregistered Sale Amount of Shares Consideration March 20, 2026 2,506,748.9395 $ 65,000,000 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned”

Apollo Origination II (UL) Capital Trust issued 580,046.4037 Shares of common stock to certain investors for $15,000,000.

“The following table details the amount of Shares sold and consideration therefor: Date of Unregistered Sale Amount of Shares Consideration March 20, 2026 580,046.4037 $ 15,000,000 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned”

CLEANSPARK, INC. issued preferred stock for special dividend of $17.1428571428571 per share.

“calculated as 2% of the Company’s earnings before interest, taxes and amortization, has been eliminated; (ii) the Series A Holders are entitled to a one-time special dividend of $17.1428571428571 per share of Series A Preferred outstanding and are otherwise not entitled to further dividends (the “Special Final Preferred Dividend”); (iii) (A) all shares of Series A”

WisdomTree, Inc. issued option to purchase up to an additional $78.75 million aggregate principal amount of the Notes of warrant to initial purchasers for granted under the Purchase Agreement, exercised in full.

“the Company also agreed to grant the Initial Purchasers an option to purchase, for settlement during a period of 13 days from, and including, the date the Notes are first issued, up to an additional $78.75 million aggregate principal amount of the Notes.”

WisdomTree, Inc. issued approximately 6.81 million shares for 2026 Notes exchange and approximately 4.19 million shares for 2029 Notes exchange of common stock to certain holders of the 2026 Notes and 2029 Notes for exchange of $75.0 million principal of 2026 Notes and $275.0 million principal of 2029 Notes; plus $0.7 million and $1.1 million cash for accrued interest, and.

“financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ̈ Item 3.02. Unregistered Sales of Equity Securities. Convertible Notes On March 23, 2026, WisdomTree, Inc. (the “Company”) priced an offering of $525.0 million aggregate principal amount of 4.50% convertible senior notes due 2031 (the “Notes”). In connection therewith,”

WisdomTree, Inc. issued $603.75 million aggregate principal amount of convertible senior notes, initially convertible at 46.3306 shares per $1,000 principal of convertible note to qualified institutional buyers under Rule 144A for $603.75 million aggregate principal amount; net proceeds ~$591.2 million.

“the notes an option to purchase up to an additional $78.75 million aggregate principal amount of the notes, which the initial purchasers exercised in full. The sale of the full $603.75 million aggregate principal amount of notes to the initial purchasers is expected to settle on March 30, 2026, subject to customary closing conditions, and to result in”

ORMAT TECHNOLOGIES, INC. issued convertible note to initial purchasers for $1 billion aggregate principal amount.

“into a Material Definitive Agreement Convertible Notes Indentures On March 20, 2026, Ormat Technologies, Inc. (the “Company”) completed its previously announced offering of $1 billion aggregate principal amount of convertible senior notes, consisting of (i) $825 million aggregate principal amount of 1.50% Series A Convertible Senior Notes due 2031 (the “Series”

Charging Robotics Inc. issued warrant.

“Reference is made to the disclosure under Item 1.01 above which is hereby incorporated in this Item 3.02 by reference. The Milestone Warrants and the shares of common stock issuable upon exercise of the Milestone Warrants have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state, and are being offered and sold in reliance on the exemption from registration under the Securities Act, afforded by Section 4(a)(2) and/or Rule 506 promulgated thereunder.”

Tempest Therapeutics, Inc. issued Series A warrants to purchase up to 925,927 shares of common stock and Series B warrants to purchase up to 925,927 shares of common stock of warrant to two institutional investors and Factor Bioscience Inc. for Included in the combined purchase price of $2.16 per share or $2.159 per pre-funded warrant.

“”). The Shares and the Common Warrants are immediately separable and will be issued separately. The combined purchase price per Share and accompanying Common Warrants is $2.16 and the combined purchase price per Pre-Funded Warrant and accompanying Common Warrants is $2.159. The gross proceeds to the Company from the Private Placement are expected to be”

Tempest Therapeutics, Inc. issued Pre-funded warrants to purchase 462,963 shares of common stock of warrant to two institutional investors and Factor Bioscience Inc. for $2.159 per pre-funded warrant and accompanying common warrants.

“”). The Shares and the Common Warrants are immediately separable and will be issued separately. The combined purchase price per Share and accompanying Common Warrants is $2.16 and the combined purchase price per Pre-Funded Warrant and accompanying Common Warrants is $2.159. The gross proceeds to the Company from the Private Placement are expected to be”

Tempest Therapeutics, Inc. issued 462,964 shares of common stock of common stock to two institutional investors and Factor Bioscience Inc. for $2.16 per share and accompanying common warrants, aggregate gross proceeds approximately $2.0 million.

“”). The Shares and the Common Warrants are immediately separable and will be issued separately. The combined purchase price per Share and accompanying Common Warrants is $2.16 and the combined purchase price per Pre-Funded Warrant and accompanying Common Warrants is $2.159. The gross proceeds to the Company from the Private Placement are expected to be”

RenovoRx, Inc. issued 5,319,392 shares of Common Stock of warrant to 15 accredited investors or qualified institutional buyers for exercise price equal to $1.751 per share for the Institutional Investors and $1.9326 for the Insiders.

“product sales) for any calendar quarter in a quarterly or annual report. The Milestone Warrants will entitle the holder to purchase Warrant Shares at an exercise price equal to $1.751 per share for the Institutional Investors and $1.9326 for the Insiders. The Milestone Warrants are subject to a beneficial ownership limitation, preventing any holder from”

RenovoRx, Inc. issued 2,200,000 shares of Common Stock of warrant to 15 accredited investors or qualified institutional buyers for price per share of Common Stock being sold to the Institutional Investors in the Offering, minus $0.0001.

“Securities Purchase Agreement, in connection with the Offering, the Company sold to the Investors an aggregate of: (i) 8,438,790 shares (the “Shares”) of common stock, par value $0.0001 per share, of the Company (the “Common Stock”), (ii) pre-funded warrants to purchase an aggregate of 2,200,000 shares of Common Stock (the “Pre-Funded Warrants”) and (iii)”

RenovoRx, Inc. issued 8,438,790 shares of common stock to 15 accredited investors or qualified institutional buyers for $0.938 per Share.

“and Milestone Warrants are referred to herein as the “Warrant Shares.” The purchase price paid by the Institutional Investors for each Share and related Milestone Warrant was $0.938. To comply with Nasdaq Stock Market rules, the purchase price paid by the Insiders for each Share and related Milestone Warrant was $1.0288. The Securities Purchase Agreement”

Crypto Co issued 151,748,756 shares of common stock to Starchive.io, Inc..

“the Company issued 151,748,756 shares of its Common Stock to Starchive pursuant to the Agreement in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended.”

Azitra, Inc. issued Series C Warrants to purchase up to 85,233,126 shares of Common Stock of warrant to the Purchasers for exercise price of $0.123 per share.

“of the Company, and a holder of more than 5% of the Company’s outstanding Common Stock as of the date of the Purchase Agreement. The Warrants will each have an exercise price of $0.123 per share (the “Exercise Price”). The PIPE Financing closed on March 20, 2026 (the “Closing Date”). The PIPE Financing could result in gross proceeds of up to approximately $31.4”

Azitra, Inc. issued Series B Warrants to purchase up to 85,233,126 shares of Common Stock of warrant to the Purchasers for exercise price of $0.123 per share.

“of the Company, and a holder of more than 5% of the Company’s outstanding Common Stock as of the date of the Purchase Agreement. The Warrants will each have an exercise price of $0.123 per share (the “Exercise Price”). The PIPE Financing closed on March 20, 2026 (the “Closing Date”). The PIPE Financing could result in gross proceeds of up to approximately $31.4”

Azitra, Inc. issued 10,485 shares of preferred stock to the Purchasers for purchase price of $1,000.00 per Security.

“of Common Stock (collectively, each share of Series A Preferred Stock and Accompanying Warrants, a “Security”). The Securities are being sold at a purchase price of $1,000.00 per Security to the Purchasers, which includes the Company’s Chief Executive Officer, a consultant of the Company, and a holder of more than 5% of the Company’s outstanding Common”

Empery Digital Inc. issued common stock.

“the Board of Directors of the Company determined that the transactions contemplated by the Securities Purchase Agreement, including the issuance and sale of the securities thereunder, constitute an "Exempt Transaction" under that certain Rights Agreement”

Empery Digital Inc. issued 4,638,219 shares of common stock (or pre-funded warrants in lieu thereof) and 4,638,219 accompanying warrants of common stock to a current institutional investor for combined offering price of $5.39 per share (or pre-funded warrant) and accompanying warrant.

“today announced that it has entered into a definitive agreement with a current institutional investor for the sale of 4,638,219 shares of common stock (or pre-funded warrants in lieu thereof) and 4,638,219 accompanying warrants to purchase shares of common stock, at a combined offering price of $5.39 per share (or pre-funded warrant) and accompanying warrant, in a registered direct offering”

Apollo Debt Solutions BDC issued 2,225,060 of common stock to feeder vehicles primarily created to hold the Fund’s Class I Common Shares for $53,711,829.

“details the shares sold: Date of Unregistered Sale Amount of Class I Common Shares Consideration As of March 2, 2026 (number of shares finalized on March 23, 2026) 2,225,060 $ 53,711,829”

Barings Private Credit Corp issued 4,923,488.173 unregistered shares of common stock to participating investors for aggregate consideration of approximately $99.3 million.

“As of March 2, 2026, Barings Private Credit Corporation (the “Company”) sold 4,923,488.173 unregistered shares (the “Sold Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (with the number of Sold Shares issued being determined on March 23, 2026) pursuant to subscription agreements entered into with the participating investors for aggregate consideration of approximately $99.3 million.”

ARES STRATEGIC INCOME FUND issued 7,089,664 of common stock for $ 190.4 million.

“The following table details the Class I common shares sold: Date of Unregistered Sales (dollar amount in millions) Amount of Class I Common Shares Total Consideration During March 2026 (number of shares finalized on March 23, 2026) 7,089,664 $ 190.4”

NEONC TECHNOLOGIES HOLDINGS, INC. issued 138,889 Shares of common stock to one investor for $1,000,000.

“The initial closing further to this third Securities Purchase Agreement took place on March 20, 2026, and consisted of the issuance of an aggregate of 138,889 Shares and Warrants to purchase 138,889 shares of Common Stock to one investor at a purchase price of $1,000,000.”

NEONC TECHNOLOGIES HOLDINGS, INC. issued Warrants to purchase 86,361 shares of Common Stock of warrant to three investors.

“The subsequent closing further to the Agreement consisted of the issuance of 86,361 Shares and Warrants to purchase 86,361 shares of Common Stock to three investors at an aggregate purchase price of $621,804.11.”

NEONC TECHNOLOGIES HOLDINGS, INC. issued 86,361 Shares of common stock to three investors for $621,804.11.

“The subsequent closing further to the Agreement consisted of the issuance of 86,361 Shares and Warrants to purchase 86,361 shares of Common Stock to three investors at an aggregate purchase price of $621,804.11.”

NEONC TECHNOLOGIES HOLDINGS, INC. issued Warrants to purchase 1,388,888 shares of Common Stock of warrant to a single institutional investor.

“The initial closing further to the Agreement consisted of the issuance of 1,388,888 Shares and Warrants to purchase 1,388,888 shares of Common Stock to a single institutional investor at a purchase price of $10 million.”

NEONC TECHNOLOGIES HOLDINGS, INC. issued 1,388,888 Shares of common stock to a single institutional investor for $10 million.

“The initial closing further to the Agreement consisted of the issuance of 1,388,888 Shares and Warrants to purchase 1,388,888 shares of Common Stock to a single institutional investor at a purchase price of $10 million.”

5C Lending Partners Corp. issued approximately 2,400,794 shares of common stock to the Company and its investors for gross proceeds of approximately $58,699,417.

“On March 20, 2026, 5C Lending Partners Corp. (the “Company”) issued and sold approximately 2,400,794 shares of common stock, par value $0.001 per share (the “Common Stock”) resulting in gross proceeds of approximately $58,699,417.”

Aureus Greenway Holdings Inc issued an aggregate of 200,000 restricted shares of common stock to C&H Capital Inc..

“The issuance of the restricted shares of Common Stock under the Consulting Agreement will constitute unregistered sales of equity securities by the Company.”

Ares Core Infrastructure Fund issued 14,208,157 shares of common stock for $354.1 million.

“In its monthly closing for March 2026, Ares Core Infrastructure Fund (the “Fund”) sold common shares of beneficial interest (“Common Shares”) for an aggregate purchase price of $354.1 million . The number of Common Shares to be issued was finalized on March 23, 2026.”

Blackstone Private Real Estate Credit & Income Fund issued 3,441,683 of common stock to participating investors for $90,000,000.

“the Common Shares sold: Date of Unregistered Sale Amount of Common Shares Consideration As of March 1, 2026 (number of Common Shares finalized on March 20, 2026) 3,441,683 $90,000,000 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto”

FEMASYS INC issued 16,378,563 Series D-1 Warrants of warrant to accredited investors for amendment and consents provided under the Amendment Agreement.

“The information set forth under Item 1.01 of this Current Report on Form 8-K regarding the issuance of the Series D-1 Warrants is incorporated by reference into this Item 3.02. The aggregate 16,378,563 Series D-1 Warrants are being issued by the Company in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), afforded by Section 4(a)(2) thereof. Each recipient of a Series D-1 Warrant is an "accredited investor" as that term is defined in Rule 501(a) of Regulation D.”

CapsoVision, Inc issued 2,867,089 shares of common stock to selected accredited investors for $4.883 per Share.

“to the Investors in the Private Placement an aggregate of 2,867,089 shares (the “Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”), at $4.883 per Share, which represents a 5% discount to the March 16th closing price, as per the terms of the agreement. The Securities Purchase Agreement contains customary representations”

BIOXYTRAN, INC issued 19,750,001 shares of common stock of warrant to accredited investors for exercise price of $0.12 per share.

“the Company also issued warrants to purchase up to 19,750,001 shares of common stock at an exercise price of $0.12 per share.”

BIOXYTRAN, INC issued 21,071,667 shares of common stock of common stock to accredited investors for $0.055 per share.

“On March 18, 2026, the Company completed the closing of a private placement of unregistered shares of common stock under Securities Purchase Agreements with certain accredited investors pursuant to which the Company issued an aggregate of 21,071,667 shares of common stock at a purchase price of approximately $0.055 per share for aggregate gross proceeds of approximately $1.2 million.”